Nephrotoxicity Clinical Trial
Official title:
Drug Disposition and Nephrotoxicity
This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.
Cisplatin (cis-diamminedichloroplatinum, Platinol®) is commonly utilized in chemotherapy regimens for the treatment of solid cancers including lung, head and neck, and cervix. Its main mechanism of action is through binding of DNA to form cross-links, leading to arrest of DNA synthesis and replication. A major adverse consequence of cisplatin therapy is acute kidney injury (AKI). It is reported that between 30 and 38 percent of patients develop signs of nephrotoxicity (toxicity in the kidneys) after a single cisplatin dose, despite strategies such as hydration to limit renal exposure. This is problematic for patients as kidney injury can delay further treatment and limit the total number of chemotherapy cycles received, thereby reducing the overall efficacy of cisplatin-containing regimens. Furthermore, it is apparent that cisplatin will remain a central component to the treatment of solid tumors in the foreseeable future. New approaches to identify patients at risk of acute kidney injury (AKI) and prevent its development and progression are urgently needed. Cisplatin causes nausea and vomiting, which requires treatment with 5-HT3 antagonists (5-HT3A) to control. Associations between the clinical use of the 5-HT3A antiemetic drugs and the risk of cisplatin AKI have recently been discovered. This study will interrogate relationships between 5-HT3A drugs (granisetron, ondansetron, and palonosetron) and cisplatin AKI. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06360666 -
Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
|
||
| Recruiting |
NCT01624324 -
Aminoglycoside Plasma Level Measurement in Neonates With Infection
|
N/A | |
| Completed |
NCT01216540 -
Vancomycin-Associated Nephrotoxicity
|
||
| Completed |
NCT01467154 -
Evaluation of Intravenous N-acetylcysteine to Prevent Contrast Media Induced Nephrotoxicity in an Emergency Center
|
N/A | |
| Recruiting |
NCT03480971 -
Treatment of Radiation and Cisplatin Induced Toxicities With Tempol
|
Phase 2 | |
| Recruiting |
NCT02528448 -
0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis
|
Phase 4 | |
| Completed |
NCT02103855 -
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
|
Phase 4 | |
| Recruiting |
NCT06153147 -
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)
|
||
| Completed |
NCT04354467 -
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
|
||
| Recruiting |
NCT05673824 -
Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.
|
Phase 4 | |
| Not yet recruiting |
NCT03438214 -
Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients
|
Phase 4 | |
| Completed |
NCT03527160 -
Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
|
||
| Completed |
NCT01848457 -
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
|
Phase 2 |